CommercialCoverageMedium impact
08.01.15g, Golimumab (Simponi Aria®) Intravenous (IV) Injection
Independence Blue Cross·Rheumatology, Gastroenterology, Dermatology·Pharmacy
Effective date
Aug 6, 2025
We identified it
Jun 19, 2026
Summary
A policy for Golimumab (Simponi Aria®) intravenous injection has been reissued and updated for commercial plans. The policy is categorized under pharmacy benefits and affects billing for this specific IV medication used to treat autoimmune conditions.
Action Required
By August 6, 2025: Billing team should review the updated Golimumab (Simponi Aria®) IV injection policy on the IBX commercial portal to understand any changes in coverage criteria, prior authorization requirements, or billing procedures. Update internal protocols and inform providers of any new requirements for this medication.